Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas‐Socias, Sylvia F. Boj, Xavier Hernando‐Momblona, Dominik Głodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fátrai, David Maussang, Jeroen J. Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nucíforo, Ramón Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan‐Otto Attolini, Elena Sancho, Héctor G. Pálmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo Price, Robert G.J. Vries, Eduard Batlle, Mark Throsby (2022). Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. , 3(4), DOI: https://doi.org/10.1038/s43018-022-00359-0.